Olatec Therapeutics Llc Is A Clinical Stage Biopharmaceutical Company Based In New Yorkfocused On Developing Nlrp3 Inflammasome Inhibitors For Treating Acute And Chronic Inflammatory Diseasesthe Company Is Advancing Oral Therapeutics That Target The Nlrp3 Pathwaywhich Plays A Significant Role In Inflammation Associated With Various Conditions The Lead Productdapansutrileis Currently In Phase 2 Trials For Early Parkinsonae S Disease And Other Indicationsit Aims To Reduce Inflammation By Inhibiting The Nlrp3 Inflammasomewhich Is Linked To Diseases Such As Gouty Arthritis And Cardiovascular Disordersolatec Has Raised $40 Million In Series A Financing To Support The Late Stage Clinical Development Of Dapansutrile And Expand Its Pipeline Of Nlrp3 Inhibitors For Conditions Like Acute Gout Flares And Chronic Kidney Disease With A Strong Emphasis On Translational Scienceolatec Is Positioned To Make Significant Contributions To The Field Of Inflammasome Therapeuticsaddressing Unmet Needs In The Treatment Of Inflammatory Diseasesthe Leadership Team Includes Experienced Professionals Dedicated To Advancing The Company S Strategic Goals
No conferences found for this company.
| Company Name | Olatec Therapeutics Llc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
